JP2018530534A5 - - Google Patents

Download PDF

Info

Publication number
JP2018530534A5
JP2018530534A5 JP2018512945A JP2018512945A JP2018530534A5 JP 2018530534 A5 JP2018530534 A5 JP 2018530534A5 JP 2018512945 A JP2018512945 A JP 2018512945A JP 2018512945 A JP2018512945 A JP 2018512945A JP 2018530534 A5 JP2018530534 A5 JP 2018530534A5
Authority
JP
Japan
Prior art keywords
allogeneic
cell population
configuration
pharmaceutical composition
human patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018512945A
Other languages
English (en)
Japanese (ja)
Other versions
JP6947720B2 (ja
JP2018530534A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/050857 external-priority patent/WO2017044678A1/en
Publication of JP2018530534A publication Critical patent/JP2018530534A/ja
Publication of JP2018530534A5 publication Critical patent/JP2018530534A5/ja
Application granted granted Critical
Publication of JP6947720B2 publication Critical patent/JP6947720B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018512945A 2015-09-10 2016-09-09 T細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法 Expired - Fee Related JP6947720B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562216525P 2015-09-10 2015-09-10
US62/216,525 2015-09-10
US201562220641P 2015-09-18 2015-09-18
US62/220,641 2015-09-18
PCT/US2016/050857 WO2017044678A1 (en) 2015-09-10 2016-09-09 Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy

Publications (3)

Publication Number Publication Date
JP2018530534A JP2018530534A (ja) 2018-10-18
JP2018530534A5 true JP2018530534A5 (enExample) 2019-11-28
JP6947720B2 JP6947720B2 (ja) 2021-10-13

Family

ID=57068181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018512945A Expired - Fee Related JP6947720B2 (ja) 2015-09-10 2016-09-09 T細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法

Country Status (14)

Country Link
US (1) US20190381098A1 (enExample)
EP (1) EP3347028A1 (enExample)
JP (1) JP6947720B2 (enExample)
KR (1) KR20180048992A (enExample)
CN (1) CN108348552A (enExample)
AU (1) AU2016320877A1 (enExample)
CA (1) CA2997757A1 (enExample)
HK (1) HK1257882A1 (enExample)
IL (1) IL257929B2 (enExample)
MX (1) MX395106B (enExample)
RU (1) RU2743381C2 (enExample)
TW (1) TWI759270B (enExample)
WO (1) WO2017044678A1 (enExample)
ZA (1) ZA201801656B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12338458B2 (en) 2017-05-25 2025-06-24 Memorial Sloan Kettering Cancer Center Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy
US11925663B2 (en) 2017-10-23 2024-03-12 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
EP3765602A1 (en) 2018-03-14 2021-01-20 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
CN111643525A (zh) * 2020-06-16 2020-09-11 济宁医学院 引发免疫排斥反应在肿瘤治疗中的应用及其方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
AR021849A1 (es) * 1998-09-30 2002-08-07 Corixa Corp Composiciones y metodos para la inmunoterapia especifica de wt1
KR101213015B1 (ko) * 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Wt1 로부터 유도된 hla-dr 결합성 항원 펩티드
FR2931163B1 (fr) * 2008-05-16 2013-01-18 Ets Francais Du Sang Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
US9738872B2 (en) * 2008-10-30 2017-08-22 Yeda Research And Development Co. Ltd. Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
AU2013207669C1 (en) * 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2018530534A5 (enExample)
Cheng et al. TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs
Harimoto et al. Inactivation of tumor‐specific CD8+ CTLs by tumor‐infiltrating tolerogenic dendritic cells
Kasturi et al. Adjuvanting a simian immunodeficiency virus vaccine with toll-like receptor ligands encapsulated in nanoparticles induces persistent antibody responses and enhanced protection in TRIM5α restrictive macaques
JP2025092558A (ja) 養子細胞療法のための改良型細胞培養方法
Schijns et al. First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo-and auto-immune tumor reactivity
JP2018520095A5 (enExample)
Wang et al. Dendritic cell therapies in transplantation revisited: deletion of recipient DCs deters the effect of therapeutic DCs
JP2019530449A5 (enExample)
RU2017143151A (ru) Способы лечения ассоциированных с вирусом эпштейна-барр лимфопролиферативных заболеваний при помощи t-клеточной терапии
RU2018112526A (ru) Способы лечения множественной миеломы и плазмоклеточного лейкоза посредством т-клеточной терапии
Motta et al. Applications of virus-specific T cell therapies post-BMT
CN102014937A (zh) 基于异基因癌细胞的免疫治疗
Northrop et al. CD8+ T-cell memory: only the good ones last
Liu et al. Immune-based therapy clinical trials in hepatocellular carcinoma
JP2018518527A5 (enExample)
Koike et al. Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma
Jofra et al. Tr1 cell immunotherapy promotes transplant tolerance via de novo Tr1 cell induction in mice and is safe and effective during acute viral infection
JP2013505296A (ja) 多発性骨髄腫細胞からの抗原ペプチドの同定
Gea-Banacloche Immunomodulation
Tournier et al. Chronic restraint stress induces severe disruption of the T‐cell specific response to tetanus toxin vaccine
AU7987391A (en) Enhancing the association of exogenous peptides with class 1 MHC molecules on immune system cells
CN105899219B (zh) 人类免疫缺陷病毒/获得性免疫缺陷综合症的治疗
Rakhmilevich et al. Presence of CD4+ T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells
Zeiser et al. Acute graft-versus-host disease-challenge for a broader application of allogeneic hematopoietic cell transplantation